Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
12/01/201610:00AMGLOBENeurocrine Biosciences (Nasdaq: NBIX) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Dec. 01, 2016 (GLOBE NEWSWIRE) -- What:  Neurocrine Biosciences (Nasdaq:NBIX), a company that discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders... More...>>
11/29/20164:15PMPRNUSNeurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatmen...
Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia Advisory Committee Meeting Scheduled for February 16, 2017 PR Newswire SAN DIEGO, Nov. 29, 2016 SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:... More...>>
11/21/20165:00PMPRNUSNeurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference Live Audio Webcast will be on November 30, 2016 PR Newswire SAN DIEGO, Nov. 21, 2016 SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/10/20161:00PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2016 London Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2016 London Healthcare Conference Live Audio Webcast will be on November 16, 2016 PR Newswire SAN DIEGO, Nov. 10, 2016 SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
11/02/20164:01PMPRNUSNeurocrine Biosciences Reports Third Quarter 2016 Results
Neurocrine Biosciences Reports Third Quarter 2016 Results -INGREZZA™ NDA for Tardive Dyskinesia Accepted for Priority Review by U.S. FDA- -Positive Elagolix Data from Endometriosis Studies Presented at American Society for Reproductive Medicine- -Enrollment Completed for Adult Study of INGREZZA in Tourette Syndrome... More...>>
10/31/20161:00PMPRNUSNeurocrine Biosciences to Present at the Credit Suisse 25th Annual Healthcare Conference
Neurocrine Biosciences to Present at the Credit Suisse 25th Annual Healthcare Conference Live Audio Webcast will be on November 7, 2016 PR Newswire SAN DIEGO, Oct. 31, 2016 SAN DIEGO, Oct. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
10/26/20161:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2016 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2016 Results Conference Call and Webcast Scheduled For Wednesday, November 2, 2016 PR Newswire SAN DIEGO, Oct. 26, 2016 SAN DIEGO, Oct. 26, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company... More...>>
10/19/20169:00AMPRNUSAbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Mens...
AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for Reproductive Medicine Scientific Congress - Elagolix shows superiority compared to placebo in reducing daily menstrual... More...>>
10/11/20166:55AMPRNUSNeurocrine Announces INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted...
Neurocrine Announces INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA PR Newswire SAN DIEGO, Oct. 11, 2016 SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and... More...>>
10/06/20168:00AMPRNUSAbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometrios...
AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congress - New detailed results to be presented on primary and secondary efficacy and safety from two pivotal Phase 3 studies... More...>>
09/07/20164:05PMPRNUSNeurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference Live Audio Webcast will be on September 13, 2016 PR Newswire SAN DIEGO, Sept. 7, 2016 SAN DIEGO, Sept. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine... More...>>
09/01/20161:00PMPRNUSNeurocrine Biosciences to Present at the Baird 2016 Healthcare Conference
Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference Live Audio Webcast will be on September 7, 2016 PR Newswire SAN DIEGO, Sept. 1, 2016 SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences... More...>>
08/31/20164:02PMPRNUSNeurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine PR Newswire SAN DIEGO, Aug. 31, 2016 SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted... More...>>
08/29/20164:02PMPRNUSNeurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia PR Newswire SAN DIEGO, Aug. 29, 2016 SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration... More...>>
08/03/20164:02PMPRNUSNeurocrine Biosciences Reports Second Quarter 2016 Results
Neurocrine Biosciences Reports Second Quarter 2016 Results -Valbenazine New Drug Application for Tardive Dyskinesia to be Submitted in 2016- - Valbenazine Presentations at Three Major Scientific Conferences during Second Quarter- -Long-Term Tourette Syndrome Study Initiated- -NBI-640756 for Essential Tremor Moves into... More...>>
07/28/20164:02PMPRNUSNeurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome Six Month Open Label Safety and Tolerability Study of Valbenazine PR Newswire SAN DIEGO, July 28, 2016 SAN DIEGO, July 28, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced... More...>>
07/27/20161:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results Conference Call and Webcast Scheduled For Wednesday, August 3, 2016 PR Newswire SAN DIEGO, July 27, 2016 SAN DIEGO, July 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company... More...>>
06/28/20168:25AMPRNUSDrugs - Generic Stocks Technical Snapshot - Sophiris Bio, Neurocrine Biosciences, Lannett, and Supernus Pharma
Drugs - Generic Stocks Technical Snapshot - Sophiris Bio, Neurocrine Biosciences, Lannett, and Supernus Pharma PR Newswire NEW YORK, June 28, 2016 NEW YORK, June 28, 2016 /PRNewswire/ -- On Monday, June 27, 2016, the NASDAQ Composite ended the trading session at 4,594.44, down 2.41%; the Dow Jones Industrial Average lost... More...>>
06/02/20163:45PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference Live Audio Webcast will be on June 8, 2016 PR Newswire SAN DIEGO, June 2, 2016 SAN DIEGO, June 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences... More...>>
05/20/20169:00AMPRNUSNeurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors PR Newswire SAN DIEGO, May 20, 2016 SAN DIEGO, May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20161204 12:13:56